Achilles Therapeutics Company
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Investors
Connections from
Total Funding:
212991704.0
Headquarters:
London, England, United Kingdom
Funding Status:
IPO
Employee Number:
1-10
Estimated Revenue:
$10M to $50M
Last Funding Type:
Grant
Technology:
Medical BioTech
Last Funding Date:
2022-07-21
Investors Number:
15.0
Founded Date:
2016-05-01
Industry:
Medical BioTech